Increase in level of tumor necrosis factor (TNF)-α in 6- hydroxydopamine-lesioned striatum in rats without influence of systemic L- DOPA on the TNF-α induction

Neuroscience Letters

Volumn 268, Issue 2, 1999, Pages 101-104

  Mogi, Makio ^a   Togari, Akifumi ^a   Tanaka, Ken Ichi ^b   Ogawa, Norio ^b   Ichinose, Hiroshi ^c   Nagatsu, Toshiharu ^c  

^a AICHI GAKUIN UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

6 Hydroxydopamine; Brain; L DOPA; Parkinson's disease; Rat; Tumor necrosis factor

Indexed keywords

LEVODOPA; OXIDOPAMINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SUBSTANTIA NIGRA;

ANIMALS; BRAIN CHEMISTRY; CORPUS STRIATUM; LEVODOPA; MALE; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033580959     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(99)00388-2     Document Type: Article

References (21)

1. Aubin N., Curet O., Deffois A., Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J. Neurochem. 71:1998;1635-1642.
2. Breitner J.C. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu. Rev. Med. 47:1996;401-411.
3. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
4. Dickson D.W., Lee S.C., Mattiace L.A., Yen S.H., Brosnan C.F. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia. 7:1993;75-82.
5. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 59:1992;1609-1623.
6. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64:1995;919-924.
7. Hartley A., Stone J.M., Heron C., Cooper J.M., Schapira A.H. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J. Neurochem. 63:1994;1987-1990.
8. Hirsch E.C., Brandel J.P., Galle P., Javoy-Agid F., Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56:1991;446-451.
9. Imaoka T., Date I., Ohmoto T., Nagatsu T. Significant behavioral recovery in Parkinson's disease model by direct intracerebral gene transfer using continuous infection of a plasmid DNA-liposome complex. Hum. Gene Ther. 9:1998;1093-1102.
10. Javoy-Agid F., Ruberg M., Taquet H., Bokobza B., Agid Y., Gaspar P., Berger B., N'Guyen-Legros J., Alvarez C., Gray F., Escourolle R., Scatton B., Rouquier L. Biochemical neuropathology of Parkinson's disease. Adv. Neurol. 40:1984;189-198.
11. Jellinger K., Linert L., Kienzl E., Herlinger E., Youdim M.B., Ben Shachar D., Riederer P. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neural Transm. 57:1996;1609-1614.
12. Matsuura K., Makino H., Ogawa N. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine. Exp. Neurol. 146:1997;526-535.
13. Mogi M., Harada M., Kojima K., Kiuchi K., Nagatsu I., Nagatsu T. Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal tyrosine hydroxylase activity in vitro and tyrosine hydroxylase content. Neurosci. Lett. 80:1987;213-218.
14. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165:1994;208-210.
15. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., Nagatsu T. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180:1994;147-150.
16. Mogi M., Togari A., Ogawa M., Ikeguchi K., Shizuma N., Fan D.S., Nakano I., Nagatsu T. Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1β and nerve growth factor in the striatum. Neurosci. Lett. 250:1998;25-28.
17. Ogawa N. Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages. Eur. Neurol. 34:1994;20-28.
18. Sacco S., Agnello D., Sottocorno M., Lozza G., Monopoli A., Villa P., Ghezzi P. Nonsteroidal anti-inflammatory drugs increase tumor necrosis factor production in the periphery but not in the central nervous system in mice and rats. J. Neurochem. 71:1998;2063-2070.
19. Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 48:1997;626-632.
20. Walkinshaw G., Waters C.M. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J. Clin. Invest. 95:1995;2458-2464.
21. Ziv I., Zilkha-Falb R., Offen D., Shirvan A., Barzilai A., Melamed E. Levodopa induces apoptosis in cultured neuronal cells, a possible accelerator of nigrostriatal degeneration of Parkinson's disease? Mov. Disord. 12:1997;17-23.